NexCourse for colorectal cancer (CRC) provides actionable results in a concise, patient-specific, correlated report with clinically relevant information to assist treatment decisions.
NexCourse CRC helps you:
- Identify important biomarkers that predict therapy response and add prognostic information
- Determine treatments to which each patient is more likely to respond favorably
- Detect which therapies are more likely to cause severe toxic side effects
Select from our suite of molecular tests to receive the necessary information for a treatment course of action. When two or more molecular tests are ordered, you will receive a concise summary of results.
NexCourse CRC test offering and treatment direction.
With a number of therapies available, our NexCourse CRC assays are the right ones to reveal the answer and give you clear direction.
| Prognosis (treatment naive) | MSI | expression can help identify the likelihood of benefit from 5-FU or capecitabine MSI in patients with Stage II disease. |
|---|---|---|
| 5-FU and capecitabine response and toxicity | TS | expression can help determine the likelihood of response to 5-FU and capecitabine. |
| DPD | can help determine the likelihood of toxicity from 5-FU and capecitabine. | |
| Oxaliplatin response | ERCC1 | expression can help determine the likelihood of response to oxaliplatin. |
| Irinotecan toxicity | UGT1A1 | can help determine the likelihood of toxicity from irinotecan. |
| EGFR-inhibitor response (cetuximab and panitumumab) |
K-RAS | mutation can help determine the likelihood of response to treatment with EGFR inhibitors cetuximab and panitumumab. |
| Prognosis | B-RAF | mutation is prognostic for survival of patients regardless of treatment. |
| Monitoring | CTC | CTCs provide helpful insights into metastatic CRC status and prognosis. |
5-FU AND CAPECITABINE1-3
TS, MSI, and DPD indicate likelihood of 5-FU-based treatment effectiveness and toxicity
- Low levels of TS expression in tumors are associated with better patient response to 5-FU and capecitabine1-3
- Patients with DPD deficiency cannot metabolize 5-FU as effectively, which predicts a higher chance of toxicity4-7
- Stage II CRC patients with MSI HIGH status tend to not benefit from 5-FU adjuvant therapy8-10
FOLFOX VS. FOLFIRI
ERCC1 and UGT1A1 help in the decision between FOLFOX and FOLFIRI treatment to increase potential effectiveness and decrease toxicity
- High levels of ERCC1 are associated with oxaliplatin resistance1
- A positive UGT1A1 mutation is associated with a decreased ability to metabolize irinotecan in FOLFIRI, resulting in an increased likelihood of severe toxicity11
- Mutations in the EGFR are prognostic with or without chemotherapy.
EGFR INHIBITORS (cetuximab and panitumumab)
K-RAS indicates likelihood of metastatic tumor response to EGFR inhibitors
- Positive K-RAS results are predictive that a patient's metastatic tumor will not respond to EGFR inhibitors12-14
- Positive B-RAF mutation is an unfavorable prognostic indicator for patients regardless of treatment
SERIAL MONITORING
Our CTC test results:
- Provide helpful insights into metastatic CRC status and prognosis15
- Are a valuable adjunct to imaging and provide similar predictive and prognostic information to imaging, but earlier15
- Can be followed over time
And, we keep your patients' test results on file so that every time you reorder their CTC, we send you a report charting their progress over time.
NexCourse™ is a registered trademark of Genoptix, Inc.